GILEAD SCIENCES, INC. SEC Filings

GILEAD SCIENCES, INC. (GILD) reported insider equity transactions by Chief Commercial and Corporate Affairs Officer Johanna Mercier. On August 17, 2026, she exercised options for 25,000 shares of common stock (23,110 at a $66.64 exercise price and 1,890 at $72.34). She then sold 28,000 shares of common stock in open-market transactions at prices ranging from $136.74 to $138.36 per share. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on February 20, 2025.

Gilead Sciences insider Johanna Mercier filed a notice to potentially sell up to 28,000 shares of common stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services program. The planned sales are associated with a stock option exercise for 25,000 shares dated 08/17/2026 and 3,000 performance shares dated 02/04/2025.

The filing lists an aggregate market value of approximately $3,853,907.85 for the securities covered and notes prior sales of 3,000 shares on 07/15/2026 for $389,757.60 and 3,000 shares on 06/15/2026 for $371,762.10.

Gilead Sciences insider Andrew Dickinson filed a notice to sell 3,000 shares of common stock of GILD through Morgan Stanley Smith Barney LLC, with an aggregate market value of $415,080.00, expected on August 17, 2026. The shares were acquired as Performance Shares on January 31, 2024. Dickinson previously sold 3,000 shares on June 15, 2026 for $376,200.00 and 3,000 shares on July 15, 2026 for $389,776.80.

Gilead Sciences, Inc. executive Keeley M Cain Wettan, EVP Gen Counsel, Legal & Comp, reported a derivative exercise on restricted stock units. On 2026-08-10, 6,002 restricted stock units converted into 6,002 shares of common stock, and 2,908 common shares at $133.06 per share were delivered or withheld for payment of exercise price or tax liability. Following the transaction, the reporting person held 13,995 restricted stock units directly.

Gilead Sciences, Inc. has filed an automatic shelf registration statement on Form S-3, allowing it to offer from time to time a broad range of securities, including senior debt, common stock, preferred stock, depositary shares, warrants, subscription rights, stock purchase contracts and stock purchase units. Specific amounts, prices and terms for each issuance will be set in future prospectus supplements.

The company’s common stock is listed on the Nasdaq Global Select Market under the symbol GILD. Authorized capital consists of 5,600,000,000 shares of common stock and 5,000,000 shares of preferred stock, with the board empowered to set the rights of any preferred series. Net proceeds from offerings under this shelf may be used for general corporate purposes.

The filing summarizes key terms of potential senior debt securities, including ranking as unsecured obligations, covenants limiting certain liens and sale-leaseback transactions (subject to a 15% consolidated net tangible asset basket), and merger and defeasance provisions under a New York law–governed indenture. It also highlights anti-takeover and exclusive-forum features in Gilead’s charter and bylaws and incorporates by reference its most recent 10-K, 10-Qs and 8-Ks for detailed financial and risk information.

Gilead Sciences reported Q2 2026 total revenues of $7,803 million, up 10% year over year, and first-half revenues of $14,763 million, up 7%. Growth was led by HIV medicines including Biktarvy and Descovy, oncology drug Trodelvy, and liver disease product Livdelzi, partly offset by sharply lower COVID-19 therapy Veklury and weaker cell therapy and HCV sales.

Despite revenue growth, Gilead posted a Q2 net loss of $10,496 million and a first-half net loss of $8,475 million, driven mainly by $11,183 million of acquired in-process R&D expenses for the Arcellx, Tubulis and Ouro Medicines deals and a $1,750 million impairment on a Trodelvy NSCLC asset. Operating cash flow remained strong at $6,117 million for the first half, while total debt, net, rose to $26,246 million. Regulatory highlights included FDA accelerated approval of Hepcludex for hepatitis delta and expanded approvals for Trodelvy, alongside full FDA approval for Tecartus and multiple late-stage oncology and HIV filings.

Gilead Sciences chairman and CEO Daniel O'Day reported selling 15,000 shares of common stock on August 3, 2026, in three transactions described as open market or private at reported prices of $129.6583, $130.8022, and $131.3433 per share. The sales were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026, with execution prices in ranges from $129.17 to $130.16, $130.18 to $131.17, and $131.21 to $131.47 per share.

Gilead Sciences reported strong base-business growth but a large loss for the quarter ended June 30, 2026. Total revenues rose 10% to $7.8 billion, with product sales excluding Veklury up 10% to $7.6 billion, led by 12% HIV growth and higher Trodelvy and Livdelzi sales.

GAAP net loss was $10.5 billion, or $(8.45) per share, versus earnings of $1.56 a year earlier, mainly from $11.2 billion of acquired IPR&D expenses tied to the Arcellx, Tubulis and Ouro Medicines acquisitions and a $1.75 billion IPR&D impairment of Immunomedics assets. Non-GAAP diluted loss per share was $(6.75), down from $2.01.

Cash, cash equivalents and marketable debt securities were $3.2 billion as of June 30, 2026, down from $10.6 billion at year-end after $11.3 billion of acquisition outflows, $2.8 billion of debt repayments and ongoing dividends and buybacks. Management now guides 2026 product sales to $30.1–$30.4 billion, with Veklury around $300 million, and expects a full-year GAAP diluted loss per share of $(3.75) to $(3.40).

An affiliate of GILD filed to sell up to 55,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated value of $7,161,550.00. The shares relate to Restricted Stock Units and Performance Stock Units dated 02/04/2025.

The filing also lists prior Rule 10b5-1 plan sales for Daniel O'Day, including 15,000 shares for $1,894,399.50 on 07/01/2026 and 15,000 shares for $1,971,846.00 on 06/01/2026.